Standard Biotools Inc. SEC filings LAB
Standard Biotools Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jun 30, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 17, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 18, 2025 |
| DEFA14A | Additional proxy material | Jun 3, 2024 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Mar 22, 2022 | — |
| DEFA14A | Additional proxy material | Mar 21, 2022 | — |
| DEFA14A | Additional proxy material | Mar 18, 2022 | — |
| DEFA14A | Additional proxy material | Mar 14, 2022 | — |
| DEFA14A | Additional proxy material | Mar 4, 2022 | — |
| DEF 14A | Proxy statement | Feb 24, 2022 | Mar 25, 2022 |
| DEFA14A | Additional proxy material | Feb 18, 2022 | — |
| DEFA14A | Additional proxy material | Feb 14, 2022 | — |
| DEFA14A | Additional proxy material | Feb 14, 2022 | — |
| PRE 14A | Preliminary proxy statement | Feb 14, 2022 | Feb 11, 2022 |
| DEFA14A | Additional proxy material | Feb 11, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | Jan 24, 2022 | — |
| DEFA14A | Additional proxy material | May 11, 2021 | — |
| DEFA14A | Additional proxy material | Apr 14, 2021 | — |
| DEF 14A | Proxy statement | Apr 14, 2021 | May 25, 2021 |
| DEFA14A | Additional proxy material | May 14, 2020 | — |
| DEF 14A | Proxy statement | May 14, 2020 | Jun 23, 2020 |
| DEFA14A | Additional proxy material | Apr 23, 2019 | — |
| DEF 14A | Proxy statement | Apr 23, 2019 | Jun 3, 2019 |
| DEF 14A | Proxy statement | Apr 27, 2018 | May 31, 2018 |
| DEF 14A | Proxy statement | Jun 29, 2017 | Aug 1, 2017 |
| DEF 14A | Proxy statement | Jun 30, 2016 | Aug 3, 2016 |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1162194
- Former names
- FLUIDIGM CORP (until Apr 1, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.